No abstract

Proton therapy accelerators in the energy range of 100-300 MeV could potentially produce intense secondary radiation, which must be carefully evaluated and shielded for the purpose of radiation safety in a densely populated hospital. Monte Carlo simulations are generally the most accurate method for accelerator shielding design. However, simplified approaches such as the commonly used point-source line-of-sight model are usually preferable on many practical occasions, especially for scoping shielding design or quick sensitivity studies. This work provides a set of reliable shielding data with reasonable coverage of common target and shielding materials for 100-300 MeV proton accelerators. The shielding data, including source terms and attenuation lengths, were derived from a consistent curve fitting process of a number of depth-dose distributions within the shield, which were systematically calculated by using MCNPX for various beam-target shield configurations. The general characteristics and qualities of this data set are presented. Possible applications in cases of single- and double-layer shielding are considered and demonstrated.

Abstract. Accurate Monte Carlo simulations and simplified methods were used to investigate the shielding requirements of a hypothetical accelerator-based boron neutron capture therapy (AB-BNCT) facility that included an accelerator room and a patient treatment room. The epithermal neutron beam for BNCT purpose was generated by coupling a neutron production target with a specially designed beam shaping assembly (BSA), which was embedded in the partition wall between the two rooms. Neutrons were produced from a beryllium target bombarded by 1-mA 30-MeV protons. The MCNP6-generated surface sources around all the exterior surfaces of the BSA were established to facilitate repeated Monte Carlo shielding calculations. In addition, three simplified models based on a point-source line-of-sight approximation were developed and their predictions were compared with the reference Monte Carlo results. The comparison determined which model resulted in better dose estimation, forming the basis of future design activities for the first AB-BNCT facility in Taiwan.